Huijun Tian, PhD

Director of Analytical Development and Quality Control at QurAlis Corporation

Speaker

Tian is the Director of Analytical Development and Quality Control supporting ASO and small molecule (SM) programs targeted on ALS, FTD, and other neurodegenerative and neurological diseases. Prior to joining QurAlis, Tian spent two and half years in Biogen, responsible for the evaluation and implementation of new technologies, validation/transfer of analytical methods, and troubleshooting method-related issues for small molecules and anti-sense oligonucleotides (ASOs) in quality control labs, such as forming the strategies to support the early-stage and late-stage SM and ASO projects (including ASOs, ASO-Ab conjugate, siRNAs) internally and externally, supporting global filings (including NDA for QALSODY (tofersen) and Zuranolone, MAA for Vumerity and others) and in-country testing (Mexico, Argentina, Chile, Brazil, Russia, etc.), method transfer work & new site qualification for commercial products (Vumerity and Spinraza). Tian has 20-year working experience in US, started her career in Eli Lilly, worked for Cubist, Cerulean Pharma, Allergan, Arrowhead Pharmaceuticals, all in analytical development and quality control for SMs and ASOs.

Tian got her PhD from University of Pittsburgh in US and her BS in Hunan University in China, all in Analytical Chemistry.